Treatment options for breast cancer resistant to anthracycline and taxane

Mayo Clinic Proceedings

Volumn 84, Issue 6, 2009, Pages 533-545

  Moreno Aspitia, Alvaro ^a   Perez, Edith A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BMS 147550; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EPOTHILONE DERIVATIVE; FLUOROURACIL; GEMCITABINE; IXABEPILONE; LAPATINIB; LETROZOLE; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; NERATINIB; PACLITAXEL; PAZOPANIB; PERTUZUMAB; TANESPIMYCIN; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID;

ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG ACTIVITY; DRUG APPROVAL; DRUG BINDING; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RESPONSE; DRUG SOLUBILITY; DRUG STRUCTURE; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; REVIEW; SCORING SYSTEM; SENSORY NEUROPATHY; STOMATITIS; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 67049133438     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/84.6.533     Document Type: Review

References (115)

1. American Cancer Society Web site. Cancer Facts & Figures 2008. http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf. Accessed April 14, 2009.
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24(14):2137-2150. (Pubitemid 46655601)
3. National Comprehensive Cancer Network Web site. NCCN Practice Guidelines in Oncology - v.1.2009: Breast Cancer. http://www.nccn.org/professionals/ physician-gls/PDF/breast.pdf. Accessed May 1, 2009.
4. Dean-Colomb W, Esteva FJ. Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer. Semin Oncol. 2008;35(2)(suppl 2):S31-S38.
5. De Laurentiis M, Cancello G, D'Agostino D, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol. 2008;26(1):44-53.
6. Peto R; Early Breast Cancer Trialists' Collaborative Group. The worldwide overview: new results for systemic adjuvant therapies. Presented at the 30th Annual San Antonia Breast Cancer Symposium; San Antonio, TX; December 13-16, 2007.
7. Kataja V, Castiglione M; ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19(2 suppl):ii11-ii13.
8. Conlin AK, Seidman AD. Taxanes in breast cancer: an update. Curr Oncol Rep. 2007;9(1):22-30. (Pubitemid 46075630)
9. Eniu A, Palmieri FM, Perez EA. Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist. 2005;10(9):665-685. (Pubitemid 41567278)
10. Perez EA. Paclitaxel in breast cancer. Oncologist. 1998;3(6):373-389. (Pubitemid 29009301)
11. Perez EA, Hillman DW, Stella PJ, et al. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer. 2000;88(1):124-131. (Pubitemid 30027687)
12. Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2001;19(22):4216-4223. (Pubitemid 33081639)
13. Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R. Weekly paclitaxel in women age 65 and above with metastatic breast cancer. Breast Cancer Res Treat. 2002;73:85-88. (Pubitemid 34548168)
14. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007 Nov 20;25(33):5210-5217. Epub 2007 Oct 29. (Pubitemid 350232252)
15. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2):185-229. (Pubitemid 38720829)
16. McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008 Apr;1785(2):96-132. Epub 2007 Nov 12.
17. Chien AJ, Moasser MM. Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Semin Oncol. 2008;35(2, suppl 2):S1-S14.
18. Fojo T, Menefee M. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann Oncol. 2007;18(suppl 5):v3-v8.
19. Brooks TA, Minderman H, O'Loughlin KL, et al. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther. 2003;2(11):1195-1205.
20. Faneyte IF, Kristel PM, Maliepaard M, et al. Expression of the breast cancer resistance protein in breast cancer. Clin Cancer Res. 2002;8(4):1068-1074. (Pubitemid 35177357)
21. Sève P, Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol. 2008;9(2):168-175. (Pubitemid 351150128)
22. Moreno A. Management of metastatic breast cancer: chemotherapy, anti-angiogenesis, other targets. Paper presented at: 18th Annual Hematology/Oncology Reviews; Amelia Island, FL; August 4-8, 2008.
23. Jones SE. Metastatic breast cancer: the treatment challenge. Clin Breast Cancer. 2008;8(3):224-233. (Pubitemid 351962143)
24. Gralow J, Rugo H, Gradishar W, et al. Novel taxane formulations in the treatment of breast cancer: a thought leader discussion and consensus roundtable. Clin Breast Cancer. 2008;8(1):33-37. (Pubitemid 351346228)
25. Moreno-Aspitia A, Perez EA. Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer. Future Oncol. 2005;1(6):755-762.
26. Wagstaff AJ, Ibbotson T, Goa KL. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Drugs. 2003;63(2):217-236. (Pubitemid 36143347)
27. Walko CM, Lindley C. Capecitabine: a review. Clin Ther. 2005;27(1):23-44.
28. Jones L, Hawkins N, Westwood M, Wright K, Richardson G, Riemsma R. Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer. Health Technol Assess. 2004;8(5):iii, xiii-xvi,1-143. (Pubitemid 38279465)
29. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20(12):2812-2823. (Pubitemid 34651510)
30. Xeloda (capecitabine) [package insert]. Nutley, NJ: Roche Pharmaceuticals; 2006. http://www.rocheexchange.com/oncology/productinformation/ xeloda?gclid=CP3XivCsmJcCFRHxDAodTFfxXQ#Product-Information. Accessed April 14, 2009.
31. Silvestris N, Cinieri S, La Torre I, et al. Role of gemcitabine in metastatic breast cancer patients: a short review. Breast. 2008 Jun;17(3):220-226. Epub 2007 Nov 26. (Pubitemid 351729153)
32. Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008;26(24):3950-3957.
33. Albain KS, Nag S, Calderillo-Ruiz G, et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival [abstract 510]. J Clin Oncol. 2004;22(14S)(July 15 suppl):510.
34. Ellis MJ, Hayes DF, Lippman ME. Treatment of metastatic breast cancer. In: Harris JR, Lippman ME, Morrow M, et al, eds. Diseases of the Breast. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:749-797.
35. Fountzilas G, Dafni U, Dimopoulos MA, et al. A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study [published online ahead of print May 16, 2008]. Breast Cancer Res Treat. doi 10.1007/s10549-008-0047-49
36. Harris JR, Morrow M, Norton L. Malignant tumors of the breast. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 5th ed. Philadelphia, PA: Lippincott; 1997:1557-1616.
37. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666-2676.
38. Gemzar (gemcitabine HCI for injection) [package insert]. Indianapolis, IN: Eli Lilly & Company; 2007. http://www.fda.gov/cder/foi/label/2006/ 020509s039lbl.pdf. Accessed April 14, 2009.
39. Chan S, Romieu G, Huober J, et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European Phase III study [abstract 581]. J Clin Oncol. 2005;23(suppl 16, pt 1):24s.
40. Dent S, Messersmith H, Trudeau M. Gemcitabine in the management of metastatic breast cancer: a systematic review. Breast Cancer Res Treat. 2008 Apr;108(3):319-331. Epub 2007 May 26.
41. Domenech GH, Vogel CL. A review of vinorelbine in the treatment of breast cancer. Clin Breast Cancer. 2001;2(2):113-128. (Pubitemid 32771563)
42. Mano M. Vinorelbine in the management of breast cancer: new perspectives, revived role in the era of targeted therapy. Cancer Treat Rev. 2006 Apr;32(2):106-118. Epub 2006 Feb 13. (Pubitemid 43362232)
43. Zelek L, Barthier S, Riofrio M, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer. 2001;92(9):2267-2272. (Pubitemid 33029069)
44. Martín M, Ruiz A, Muñoz M, et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol. 2007;8(3):219-225. (Pubitemid 46291704)
45. Estévez LG, Batista N, Sánchez-Rovira P, et al. A Phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Clin Breast Cancer. 2008;8(2):149-154. (Pubitemid 351655929)
46. Lorusso V, Manzione L, Silvestris N. Role of liposomal anthracyclines in breast cancer. Ann Oncol. 2007;18(suppl 6):vi70-vi73.
47. Rivera E. Liposomal anthracyclines in metastatic breast cancer: clinical update. Oncologist. 2003;8(suppl 2):3-9. (Pubitemid 37152051)
48. Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2001;19(5):1444-1454. (Pubitemid 32202552)
49. Harris L, Batist G, Belt R, et al; TLC D-99 Study Group. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002;94(1):25-36. (Pubitemid 34049039)
50. O'Brien ME, Wigler N, Inbar M, et al; CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440-449. (Pubitemid 38444547)
51. Keller AM, Mennel RG, Georgoulias VA, et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol. 2004;22(19):3893-3901. (Pubitemid 41079870)
52. Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel [published correction appears in Clin Cancer Res. 2006;12(12):3869]. Clin Cancer Res. 2006;12(4):1317-1324. (Pubitemid 43342524)
53. Abraxane (albumin-bound paclitaxel) [package insert]. Los Angeles, CA: Abraxis Bioscience, Inc. May 2007. http://www.fda.gov/cder/foi/label/2008/ 021660s013lbl.pdf. Accessed November, 2008.
54. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005 Nov;23(31):7794-7803. Epub 2005 Sep 19. (Pubitemid 46657376)
55. Blum JL, Savin MA, Edelman G, et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer. 2007;7(11):850-856.
56. Gradishar W, Krasnojon D, Cheporov S, Makhson A, Manikhas G, Hawkins G. A randomized phase 2 trial of qw or q3w ABI-007 (ABX) vs. q3W solvent-based docetaxel (TXT) as first-line therapy in metastatic breast cancer (MBC) [abstract 46]. Breast Cancer Res Treat. 2006;100(suppl 1):S21.
57. Cortes J, Baselga J. Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist. 2007;12(3):271-280. (Pubitemid 46556793)
58. Gerth K, Bedorf N, Höfle G, Irschik H, Reichenbach H. Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria): production, physico-chemical and biological properties. J Antibiot (Tokyo). 1996;49(6):560-563. (Pubitemid 26235665)
59. Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J Clin Oncol. 2004;22(10):2015-2025.
60. Bode CJ, Gupta ML Jr, Reiff EA, Suprenant KA, Georg GI, Himes RH. Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules [published correction appears in Biochemistry. 2002;41(24);7858]. Biochemistry. 2002;41(12):3870-3874. (Pubitemid 34251025)
61. Vahdat L. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms. Oncologist. 2008;13(3):214-221. (Pubitemid 351679896)
62. Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 2001;7(5):1429-1437. (Pubitemid 32708699)
63. Lee FY, Smykla R, Johnston K, et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol. 2009 Jan;63(2):201-212. Epub 2008 Mar 19.
64. Jordon M, Miller H, Ni L, et al. The Pat-21 breast cancer model derived from a patient with primary Taxol resistance recapitulates the phenotype of its origin, has altered beta-tubulin expression and is sensitive to ixabepilone [abstract LB-280]. Proc Am Assoc Cancer Res. 2006;47:73.
65. Denduluri N, Low JA, Lee JJ, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol. 2007 Aug 10;25(23):3421-3427. Epub 2007 Jul 2. (Pubitemid 47310878)
66. Low JA, Wedam SB, Lee JJ, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol. 2005;23(12):2726-2734. (Pubitemid 46179462)
67. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007 Aug 10;25(23):3407-3414. Epub 2007 Jul 2. (Pubitemid 47310876)
68. Roché H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol. 2007 Aug 10;25(23):3415-3420. Epub 2007 Jul 2. (Pubitemid 47310877)
69. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol. 2007 Aug 10;25(23):3399-3406. Epub 2007 Jul 2. (Pubitemid 47310875)
70. Lee FY, Camuso A, Castenada S, et al. Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts. [abstract 12017]. J Clin Oncol. 2006;24(suppl 18)(pt 1):597s.
71. Hortobagyi GN, Perez E, Vrdoljak E, et al. Analysis of overall survival (OS) among patients (pts) with metastatic breast cancer (MBC) receiving either ixabepilone (I) plus capecitabine (C) or c alone: results from two randomized phase III trials [abstract 186]. In: Proceedings from ASCO Breast Cancer Symposium 2008. Washington, DC: September 5-7, 2008. http://www.asco.org/ASCO/ Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst-detail-view&confID= 58&abstractID=40389. Accessed April 14, 2009.
72. Ixempra kit (ixabepilone) for injection [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2007. http://packageinserts.bms.com/pi/pi-ixempra. pdf. Accessed April 14, 2009.
73. Avastin (bevacizumab) [package insert]. San Francisco, CA: Genentech, Inc; 2008. http://www.gene.com/gene/products/information/pdf /avastin-prescribing.pdf. Accessed April 14, 2009.
74. Miles D, Chan A, Romieu G, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO [abstract LBA1011]. J Clin Oncol. 2008; 26(suppl 15):43s.
75. Sledge G, Miller K, Moise C, Gradishar W. Safety and efficacy of capecitabline (C) plus bevacizumab (B) as first-line in metastatic breast cancer [abstract 1013]. J Clin Oncol. 2007;25(suppl 18):35s.
76. Perez EA, Hillman DW, Kugler JW, Steen PD, Fitch TR, Rowland KM. North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first line chemotherapy for patients with metastatic breast cancer [abstract 2069]. Breast Cancer Res Treat. 2006;100(suppl 1):S104.
77. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23(4):792-799. (Pubitemid 46224178)
78. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004;5(1):63-69. (Pubitemid 38821193)
79. Sjögren S, Inganäs M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol. 1998;16(2):462-469. (Pubitemid 28135587)
80. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-182. (Pubitemid 17231334)
81. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127-137. (Pubitemid 33674041)
82. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-792. (Pubitemid 32222155)
83. Herceptin (trastuzumab) [package insert]. San Francisco, CA: Genentech Inc; 2009. http://www.gene.com/gene/products/information/pdf/herceptin- prescribing.pdf. Accessed April 15, 2009.
84. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17(9):2639-2648. (Pubitemid 29415219)
85. Fountzilas G, Razis E, Tsavdaridis D, et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group. Clin Breast Cancer. 2003;4(2):120-125. (Pubitemid 36939418)
86. Gelmon KA, Mackey J, Verma S, et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer. 2004;5(1):52-58. (Pubitemid 38821191)
87. Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V. Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC). Onkologie. 2005;28(11):582-586. (Pubitemid 41513144)
88. Tripathy D, Slamon DJ, Cobleigh M, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004;22(6):1063-1070. (Pubitemid 41095039)
89. Von Mickwitz G, Zielinski C, Maarteense E, et al. Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: the TBP phase III study (GBG 26/BIG 3-05) [abstract 1025]. J Clin Oncol. 2008;26(suppl 15):47s.
90. Moy B, Goss PE. Lapatinib: current status and future directions in breast cancer. Oncologist. 2006;11(10):1047-1057. (Pubitemid 44788395)
91. Tykerb (lapatinib) tablets [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2008. http://us.gsk.com/products/assets/us-tykerb.pdf. Accessed April 15, 2009.
92. Di Leo A, Gomez HL, Aziz Z, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as firstline treatment for metastatic breast cancer [published correction appears in J Clin Oncol. 2009;27(11):1923]. J Clin Oncol. 2008 Dec 1;26(34):5544-5552. Epub 2008 Oct 27.
93. Johnston S, Pegram M, Press M, et al. Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): final results from the EGF30008 trial [abstract 46]. Cancer Res. 2009;69(suppl 2).
94. Bender LM, Nahta R. Her2 cross talk and therapeutic resistance in breast cancer. Front Biosci. 2008;13:3906-3912. (Pubitemid 351594668)
95. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006;3(5):269-280. (Pubitemid 43731112)
96. Beeram M, Burris HA, Modi S, et al. A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+ breast cancer (BC) [abstract 1028]. J Clin Oncol. 2008;26(suppl 15):48s.
97. Baselga J, Imadalou K, Paton V, Gray D, Swain S. Efficacy, safety and tolerability of dual monoclonal antibody therapy with pertuzumab + trastuzumab in HER2+ metastatic breast cancer patients previously treated with trastuzumab [abstract 3138]. Cancer Res. 2009;69(suppl 2):249s.
98. Burstein HJ, Sun Y, Tan AR, et al. Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor: phase 2 results in patients with advanced HER2+ breast cancer [abstract 37]. Cancer Res. 2009;69(suppl) 2:73s.
99. Whenham N, D'Hondt V, Piccart MJ. HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies. Clin Breast Cancer. 2008;8(1):38-49. (Pubitemid 351346229)
100. Widakowich C, Dinh P, de Azambuja E, Awada A, Piccart-Gebhart M. HER-2 postitive breast cancer: what else beyond trastuzumab-based therapy? Anti-Cancer Agents Med Chem. 2008;8(5):488-496. http://www.benthamdirect.org/pages/content. php?ACAMC/2008/00000008/00000005/0005W.SGM. Accessed April 15, 2009.
101. Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early stage breast cancer. J Clin Oncol. 2006 Dec 20;24(36):5652-5657. Epub 2006 Nov 20. (Pubitemid 46631305)
102. Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008;68(9):3108-3114.
103. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329-2334. (Pubitemid 46698581)
104. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11(16):5678-5685. (Pubitemid 41170290)
105. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007;8(3):235-244. (Pubitemid 46291713)
106. Finn RS, Dering J, Ginther C, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat. 2007 Nov;105(3):319-326. Epub 2007 Feb 1.
107. Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 2007;9(5):R65. (Pubitemid 350187481)
108. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008;26(15):2568-2581.
109. Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer [abstract 1009]. J Clin Oncol. 2008;26(suppl 15):43s.
110. O'Shaughnessy J, Weckstein DJ, Vukelja SJ. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer [abstract 308]. Breast Cancer Res Treat. 2007;106(suppl 1):S32.
111. Finn RS, Bengala C, Ibrahim N, et al. Phase II trial of dasatinib in triplenegative breast cancer: results of study CA180059 [abstract 3118]. Poster presented at: 31st San Antonio Breast Cancer Symposium. San Antonio, TX: December 11, 2008. http://www.posters2view.com/sabcs08/viewp.php?nu=3118. Accessed April 15, 2009.
112. Thome S, Hobday T, Hillman D, et al. Translational correlates, including outcome for patients with ER-/PR-/HER2-(triple negative [TNeg]) disease from N0234, a phase II trial of gemcitabine and erlotinib for pts with previously treated metastatic breast cancer (MBC) [abstract 1071]. J Clin Oncol. 2007;25(suppl 18):49s.
113. O'Shaughnessy J, Osborne C, Blum J, et al. Triple negative breast cancer: a phase 2, multi-center, open-label, randomized trial of gemcitabine/ carboplatin (G/C), with or without BSI-201, a PARP inhibitor [abstract 2120]. Cancer Res. 2009;69(suppl 2):194s.
114. Rugo HS, Roché H, Thomas E, et al. Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies [abstract 3057]. Cancer Res. 2009;69(suppl 18):225s.
115. Michaud LB. Treatment-experienced breast cancer. Am J Health Syst Pharm. 2008;65(10)(suppl 3):S4-S9.